Grünenthal Press Releases 2012
Welcome to Grünenthal's Press Overview
16 Oct 2012
INTAC® – Grünenthal Group presents data demonstrating the strength of its tamper resistant technology at the American Association of Pharmaceutical Science Annual Meeting and Exposition.
Bedminster, NJ/Aachen, Germany – October 16, 2012. Grünenthal, a global family-owned pharmaceutical company specializing in pain management, today announced that data will be presented in two posters at this year’s annual meeting of the American Association of Pharmaceutical Science taking place in Chicago, IL from October 14 – 18, 2012.
05 Sep 2012
The company will present development and characteristics of tablets using INTAC® technology during a poster session and Meet-the-Expert presentations at its booth
Bedminster, NJ/Aachen, Germany – September 5, 2012. Grünenthal, a global family-owned pharmaceutical company specializing in pain management, today announced the company’s planned activities at this year’s PAINWeek®, the National Conference on Pain for Frontline Practitioners, taking place in Las Vegas, NV from September 5 – 8, 2012.
11 Jul 2012
Grünenthal to present its Tamper Resistant Formulation Technology INTAC® at the Meeting & Exposition of the Controlled Release Society
Bedminster, NJ – July 12, 2012. This year’s 39th Annual Meeting and Exposition of the Controlled Release Society (CRS) will take place in Quebec City, Canada from July 15-18, 2012. Grünenthal’s participation in the event will include a booth exhibition as well as hosting an interactive Releasing Technology Workshop.
14 Jun 2012
Aachen, June 14th, 2012 - New chemical entities (NCE) in the areas of pain and inflammation as well as the formulation technology platform INTAC® are at the core of Grünenthal’s presentation at BIO International Convention 2012.
07 Jun 2012
From the Bench-top to the Users
Bedminster, NJ – June 7, 2012. During this year’s 74th Annual Meeting of the College on Problems of Drug Dependence (CPDD) taking place from June 9-14, 2012 in Palm Springs, CA, Marta Sokolowska, Director of The Center of Excellence for Abuse Liability at Grunenthal USA, Inc., together with Kerri A. Schoedel (INC Research Toronto), will co-chair a workshop assessing abuse and tamper resistant technologies.
15 May 2012
Clinical Data on Grünenthal’s Tamper Resistant Formulation Technology to be presented at APS
Bedminster, NJ – May 15, 2012. During this year’s Annual Scientific Meeting of the American Pain Society (May 16-19, 2012 • Honolulu, HI) Grünenthal will present results from clinical studies utilizing a product based on its INTAC formulation technology. INTACis designed to be crush-resistant and to protect intended action of extended release drugs. Applying INTAC to prescription opioid drugs is considered an efficient means to combat unintended and intended drug misuse and abuse through tampering with the formulation.
03 May 2012
Bedminster, NJ – April 30, 2012. During this year's Drug and Delivery Formulations Summit (San Diego, CA) Grünenthal presents its new INTAC formulation technology designed to be crush-resistant and to protect intended action of extended release prescription opioid drugs.